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Abstract
CD19-targeting CAR T cells have shown potency in clinical trials targeting B cell leukemia.
Although mainly second generation (2G) CARs carrying CD28 or 4-1BB have been investi-
gated in patients, preclinical studies suggest that third generation (3G) CARs with both
CD28 and 4-1BB have enhanced capacity. However, little is known about the intracellular
signaling pathways downstream of CARs. In the present work, we have analyzed the signal-
ing capacity post antigen stimulation in both 2G and 3G CARs. 3G CAR T cells expanded
better than 2G CAR T cells upon repeated stimulation with IL-2 and autologous B cells. An
antigen-driven accumulation of CAR+ cells was evident post antigen stimulation. The cyto-
toxicity of both 2G and 3G CAR T cells was maintained by repeated stimulation. The phos-
phorylation status of intracellular signaling proteins post antigen stimulation showed that 3G
CAR T cells had a higher activation status than 2G. Several proteins involved in signaling
downstream the TCR were activated, as were proteins involved in the cell cycle, cell adhe-
sion and exocytosis. In conclusion, 3G CAR T cells had a higher degree of intracellular sig-
naling activity than 2G CARs which may explain the increased proliferative capacity seen in
3G CAR T cells. The study also indicates that there may be other signaling pathways to con-
sider when designing or evaluating new generations of CARs.
Introduction
T cells engineered with chimeric antigen receptors (CARs) have shown promising results in
patients with hematological malignancies [1–5]. CARs consist of the single chain fragment
(scFv) of an antibody fused to a signaling chain e.g. the zeta chain of the TCR/CD3 complex
[6]. The first generation (1G) CARs specifically killed target cells and secreted IL-2 upon target
recognition in vitro [6], but had limited expansion and in vivo persistence in the clinic [7–9].
Therefore, a costimulatory endodomain derived from either CD28, 4-1BB or OX40 has been
added to the constructs to form a second generation (2G) CAR. Inclusion of CD28 in 2G CARs
increased T cell proliferation [10–13], increased cytokine secretion upon target recognition
[13–15], promoted CAR T cell persistence to T regulatory cells (Tregs), IL-10 and TGFβ [10]
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and improved antitumor effect in in vivomodels [16]. CARs containing 4-1BB showed an
increased cytokine secretion, an upregulation of anti-apoptotic genes and enhanced in vivo per-
sistence [17–19]. 2G CARs containing 4-1BB have so far shown the most persistent results in
patients. In the first report, two out of the three treated chronic lymphocytic leukemia (CLL)
patients had complete responses [2]. To date, multiple patients have been treated with the 4-
1BB or CD28 2G CAR and impressive effects have been noted in leukemic patients [1–3, 5],
and lately also in lymphoma [4]. However, lymphoma patients need critical levels of precondi-
tioning to reach complete response, which may be due to the solid character of these tumors.
To further strengthen CARs, third generation (3G) CARs that contain two co-stimulatory ele-
ments, for example from both the CD28 and 4-1BB intracellular portions, have been developed
[20–26]. The addition of 4-1BB as a second co-stimulatory molecule in the 2G CD28 CAR con-
struct rendered more potent in vivo tumor responses [18]. CARs containing 4-1BB or both
CD28 and 4-1BB have also showed superior in vivo expansion and anti-tumor efficacy com-
pared to CARs carrying CD28 [19, 27]. The persistence of 4-1BB or CD28 2G CAR T cells in
patients has been discussed [28] and in clinical trials so far, it appears that time to relapse is
longer in patients treated with CARs containing 4-1BB compared to CD28 CARs, indicating
an increased persistence of the 4-1BB CAR T cells [5, 29, 30]. Despite increasing knowledge of
the therapeutic effect of 2G and 3G CAR T cells, studies of the intracellular signaling down-
stream CAR is lacking.
In the present study, we compare 2G CAR T cells containing CD28 to a 3G CAR containing
both CD28 and 4-1BB to generate a rationale for the use of the latter in clinical trials. We inves-
tigated the functional capacity of 3G compared to 2G CARs and have initiated a mapping of
the intracellular signaling capacity post antigen stimulation in both 2G and 3G CARs.
Materials and Methods
Patient material
PBMCs were isolated from blood of patients with CLL (n = 4) or healthy donors (n = 2) using
Ficoll paque gradient centrifugation (Ficoll paque Premium; GE healthcare Life sciences, cat
no 17-5442-03). Written consent was obtained from all patients in concordance with the Hel-
sinki Declaration and the study was approved by the Uppsala Regional Ethical Review Board,
Uppsala, Sweden (DNr: 2006:145). Peripheral blood from healthy donors was obtained from
the blood bank at Uppsala University Hospital. Deidentified cord blood (CB) units were
obtained through the MD Anderson Cord Blood Bank (University of Texas, Houston, TX) on
a Baylor College of Medicine (BCM) IRB-approved protocol.
Cell culture
CD19+ Daudi [31] (EBV positive Burkitt’s lymphoma) and CD19- K562 (chronic myeloid leu-
kemia (CML) cell line and NK target) was purchased from ATCC (cat no CCL-213 and CCL-
243, respectively) and cultured in RPMI medium (cat no 21875–034) supplemented with 10%
fetal bovine serum (cat no 10500–064) and 1% Penicillin-Streptavidin (cat no 15140–122).
293T (ATCC, cat no CRL-3216) was cultured in IMDMmedium (cat no 12440–053) supple-
mented with 10% fetal bovine serum, 1% Penicillin-Streptavidin and 0.1% Sodium Pyruvate
(cat no 11360–070). All cell culture components were purchased from Life Technologies.
Plasmid construction and retrovirus production
The plasmid pRSV-γ [6] contained the original CAR gene consisting of a scFv from an anti-
body combined with the gamma (γ) chain. To construct a CD19-targeting CAR, the scFv in the
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pRSV-γ was changed to an anti-CD19 scFv subcloned from the pHBStrep plasmid [32]. The
CAR has a hinge domain with the CH2-CH3 motif (long hinge) to link the scFv to the intracel-
lular domain. To increase signaling from the CAR, the γ-chain was changed to the intracellular
part of the CD3-zeta (z) chain subcloned from the pGEMz plasmid [33]. The CAR construct
was then subcloned into the murine Moloney based retroviral backbone plasmid SFG [34].
This step completed the 1G CAR construct that has been used to generate 2G and 3G CAR T
cells in the present study. The transmembrane and intracellular region of CD28 was inserted
into the SFG after the hinge and prior to the CD3-z by recombination to generate 2G CAR T
cells [10]. Finally, the intracellular region of 4-1BB was inserted between the CD28 and CD3-z
regions to create the 3G CAR construct: SFG.CAR.CD19.28.4-1BBzeta. Virus vectors were pro-
duced through Genejuice-mediated (Genejuice; Novagen Inc, cat no 70967) transfection of
293T cells with the vector plasmid together with plasmids containing the gag-pol genes (Peg-
Pam; gift of Dr Elio Vanin, Baylor College of Medicin, Houston, TX, USA), and the RD114
envelope (RDF-114; gift of Mary Collins, London, UK). 2G, 3G and Mock (empty vector) virus
were made in parallel. Viral supernatants were harvested after 48 and 72 hours, frozen and
stored at -80°C.
Generation of CAR T cells
CAR T cells were generated from peripheral mononuclear blood cells (PBMCs) and cultured in
RPMI medium supplemented with 10% fetal bovine serum and 1% Penicillin-Streptavidin,
all purchased from Life Technologies. B cells were isolated using αCD20 magnetic beads
(CD19+ cells post isolation; mean 96.4% ranging from 90.5 to 99.5%) and T cells were subse-
quently purified from the CD20 negative fraction using pan T magnetic beads (CD3+ cells post
isolation; mean 99.3% ranging from 99 to 99.7%), both fromMiltenyi Biotec GmbH (cat no
130-091-104 and 130-096-535, respectively). T cells were activated with 1μg OKT-3/mL
(Biolegend, cat no 317315) at day 0. On day 2, T cells were stimulated with 100IU IL-2/mL
(Proleukin1, Novartis) and the following day (day 3) transduced on RetroNectin-coated (Ret-
roNectin; Takara Bio Inc, cat no T100B) plates pre-incubated with retroviral supernatant and
kept in 100IU IL-2/ml.
T cell culture with repeated antigen stimulation
B cells were isolated from PBMCs through αCD20 magnetic bead isolation. CD20 negative
cells were subsequently purified using pan T magnetic beads to generate CAR T cells (Miltenyi
Biotec GmbH). Due to the slow proliferative capacity of T cells generated from leukemic
patients, the expansion was ongoing for 14 days. On day 14, 1x106 CAR T cells were cultured
without stimuli or stimulated with 50IU IL-2/ml twice a week and/or autologous B cells (1:4
ratio, B:T) once a week (S1 Fig) similarly as a previously established protocol to generate EBV
specific T cells by stimulating T cells with EBV infected B cells. The cells were harvested and
counted once a week during one month’s time. For non-expanding cell cultures, all cells were
replated and additions of B cells where calculated based on remaining T cell number in order
to maintain the 4:1 T to B cell ratio. In cultures containing more than 1x106 cells, excess cells
were used for flow cytometry and 1x106 cells replated. Proteins were extracted from untrans-
duced, Mock, 2G CAR and 3G CAR transduced T cells at day 14 (before co-culture) and 3 days
after the last B cell stimulation (endpoint of co-culture) and used for Western blot and cell sig-
naling multiplex assay. Cell culture supernatants were collected 24h after B cell stimulation
(once/week), and analyzed for IFNγ (ELI-pair; Diaclone, 851.560.005) and Granzyme B (Dia-
clone, cat no 850.790.096) using ELISA.
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Flow cytometry
Cells were incubated with 1% BSA in PBS for 10 min, centrifuged and stained for 15 min
with the following antibodies: CD3-FITC (cat no 300406), CD4-APC/Cy7 (cat no 300518),
CD8-PE/Cy7 (cat no 301012), CD19-PerCP (cat no 302228), CCR7-BV421 (cat no 353208),
CD45RA-APC/Cy7 (cat no 304128), CD27-PE (cat no 302808), CD28-PE/Cy7 (cat no
302926), Tim-3-BV421 (cat no 345007), PD-1-PE (cat no 329906) all purchased from Biole-
gend, α-CAR-DyLight649 AffiniPure F(ab')2 Fragment Goat Anti-Human IgG (H+L) pur-
chased from Jackson ImmunoResearch Europe LTD (cat no 109-496-088), or negative isotype
control antibodies (Biolegend). Cells were washed with PBS. Analyzed on BD Canto II (BD
Biosciences, San Jose, CA) and evaluated with FlowJo (Treestar, Ashland, OR, USA). The
transduction efficiency of 3G CAR was lower than that of 2G CAR. Therefore, a correction fac-
tor was calculated based on the CAR expression of the 2G and 3G T cells from the same donor
at the same time point. This correction factor was then used to normalize the values of the
functional assays.
Kinase assay
B cells were isolated from PBMCs through αCD20 magnetic bead (Miltenyi Biotec GmbH) iso-
lation and the CD20 negative fraction was subsequently purified using pan T magnetic beads
all according to manufacturer’s protocol. Pan T purified T cells were used to generate Mock,
2G and 3G CAR T cells. The T cells were stimulated with αCD20-labelled B cells (4:1 ratio) for
1 and 3h. At these time-points the co-culture was run through a LS column (Miltenyi Biotec
GmbH) and the T cell fractions (99.9% CD3+) were washed with cold PBS and resuspended in
lysis buffer containing M-PER mammalian protein extraction reagent (cat no 78503) supple-
mented with 1% Halt phosphatase inhibitor cocktail (cat no 78415) and 1% protease inhibitor
cocktail (cat no 1861277) all from Thermo Scientific. Protein lysates were assayed for kinase
tyrosine phosphorylation analyzed on PamStation12 (PamGene, 's-Hertogenbosch, The
Netherlands).
Cell signaling multiplex assay
The MILLIPLEX1MAP T-Cell Receptor Signaling Magnetic Bead Kit 7-Plex fromMillipore
Merck (cat no 48-690MAG) was used to detect changes in phosphorylated CREB (Ser133),
Erk/MAP kinase 1/2 (Thr185/Tyr187), and phosphorylated tyrosine residues on CD3 epsilon
chain, Lck, ZAP-70, LAT, and Syk in T cell lysates from day 14, hence before and 3 days after
the last B cell stimulation (endpoint of the co-culture). The assay was set up according to man-
ufacturer’s instructions loading 15μg protein/well and analyzed on the Luminex1 system.
51Chromium-release assay
Target cells (Daudi and K562) were labeled with radioactive chromium (51Cr, PerkinElmer, cat
no NEZ030S005MC) for 2 hours and subsequently washed prior to co-culture with CAR T
cells at different ratios for 4 hours. Co-culture supernatants were mixed with Optiphase super-
mix (PerkinElmer, cat no 1200–434) and analyzed on the beta counter Wallac Trilux, 1450
microbeta (PerkinElmer, Waltham, MA, USA). Cytotoxicity (% lysis) was calculated as follows:
(sample-spontaneous release)/(maximum release–spontaneous release) x 100.
In vivo experiments
C57BL/6J nu/nu mice (Taconic M&B, Ry, Denmark) were injected subcutaneously with 5x106
Daudi cells mixed 1:1 with Matrigel (BD Biosciences, cat no 354248) and treated upon
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measurable tumor (2 weeks post tumor cell injection) with 5x106 2G, 3G or mock transduced
human T cells via i.p. injection (6 mice per group). Survival and tumor size was monitored
throughout the experiment using a caliper. Mice were euthanized if tumor1cm2. Animals
were housed at the Rudbeck Animal Facility and cared for by the staff according to local regula-
tions. The in vivo experiments were approved by Uppsala Animal Ethics Committee (ref no:
C319/9).
NSG mice 6 weeks of age (Jackson laboratories) were sublethally irradiated (280Gy) and
engrafted with 2x105 CD34+ cells selected from umbilical cord blood (UCB) units (fromMD
Anderson UCB bank, under BCM approved protocol). Engraftment was confirmed within 6
weeks by measuring human CD45+ and CD19+ cells in the peripheral blood by flow cytometry.
Engrafted mice received via tail injection T cells derived from the corresponding UCB negative
fraction, transduced with 2G or 3G vector construct and further labeled with FFluc (3x106/
mouse). In vivo expansion of T cells was monitored over time by IVIS imaging (Xenogen, Cali-
per Life Sciences Hopkinton, MA), while the elimination of CD19+ cell was measured by flow
cytometry of peripheral blood samples. By day 60 or 100 mice were euthanized and spleen,
bone marrow and blood collected for flow cytometry analysis (human CD45+ and CD3+). CAR
expression by T cells was detected using the Cy-5-conjugated goat anti human IgG (H+L) anti-
body (Jackson ImmunoResearch) that recognizes the human IgG1-CH2-CH3 component
incorporated as a spacer region within the CARs. Samples were analyzed in a FACSCalibur
(BD Pharmingen) and were analyzed by CellQuest pro software (BD Biosciences). At least
10000 positive events were acquired in each sample. The NSG mice were maintained at Baylor
College of Medicine Animal Facility on a BCM IACUC approved protocol.
Statistical analysis
Statistical evaluations were performed using GraphPad Prism (GraphPad Software, La Jolla,
CA). Differences between groups generating p-values<0.05 were considered significantly
different.
Results
CAR is expressed on transduced T cells
Activated T cells from healthy donors and CLL patients were efficiently transduced with Mock,
2G or 3G virus (MLV vector), resulting in a median 2G CAR expression of 33% ranging from 5
to 90% and a 3G median CAR expression of 27.1% ranging from 3 to 87% at day 14,prior to
stimulation. There was a difference in CAR expression when comparing 2G and 3G CAR and
also between donors. Therefore, to enable comparison of 3G CAR T cells to 2G, CAR expres-
sion was normalized for all functional assays. T cells were expanded with autologous B cells,
IL-2 or a combination of the two. After one month’s expansion, CAR T cells stimulated with
both B cells and IL-2 had a significantly larger fraction of CAR positive cells (Fig 1B and 1D) as
well as a higher intensity of expression (data not shown) while CAR T cells cultured with IL-2
alone maintained the same expression level (Fig 1A and 1C). T cells stimulated with B cells
alone did not survive during the culture assay since they depended on IL2, hence, no reliable
analysis could be performed.
CAR T cells exhibited a memory-like phenotype and low expression of
exhaustion markers
3G CAR T cells were harvested and phenotyped using multicolor flow cytometry before and
after one month’s stimulation with IL-2 +/- B cells. As controls, 2G CAR T cells and Mock
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transduced T cells were used. The majority of cells were of CD8 lineage, yet there were CD4+ T
cells present in all cultures (from all donors) (Fig 2A). CAR positive cells showed no difference
in CD4/CD8 ratio before or after co-culture, nor was there a difference seen when comparing
CAR negative and CAR positive T cells within the cultures (data not shown). The skewing
towards CD8+ phenotype was not dependent on transduction but rather dependent on the
OKT-3/IL-2 activation. Exhaustion was defined as PD-1+/Tim-3+ double positive cells and
were found in less than 16% of the total cell number (Fig 2B). There was no significant difference
within the cohorts before and after co-culture. However, CAR- T cells in the 3G CAR culture
showed significantly lower number of PD-1+/Tim-3+ cells compared to the CAR+ fraction (data
not shown).
An extended T cell phenotype was determined in the different groups before and after
expansion. The phenotypes were defined as follows; naïve: CD45RA+ CCR7+, effector: CD45RA
+ CCR7-, central memory: CD45RA- CCR7+ and effector memory: CD45RA- CCR7-. CAR or
Mock transduced T cells had a similar phenotype prior to co-culture independently of CAR
expression. The majority of T cells had a memory-like phenotype of either central or effector
type (Fig 2C). After expansion with IL-2 and B cells 3G CAR T cells showed a tendency to
increased number of effector memory cells that, however, did not reach significance due to donor
variance (3G: p = 0.0836, 2G: p = 0.1232) compared to cells cultured with IL-2 alone. There was
also a tendency to increased number of central memory cells compared to before co-culture (3G:
p = 0.0625, 2G: p = 0.0625). Cells of effector phenotype showed a tendency to decreased cell
number (3G: p = 0.0625, 2G: p = 0.0625) compared to before expansion (Fig 2C). Interestingly,
the phenotypically naïve population was maintained despite repeated stimulations with antigen.
Hence, the majority of 3G CAR T cells were CD8+memory cells, expressing low levels of exhaus-
tion markers. The phenotype was also analyzed on the CAR- cells within the 2G and 3G groups.
These cells did not change their phenotype post expansion, which was expected since the cells
had not been stimulated with antigen (S2 Fig).
Fig 1. Transduced T cells express CAR. CAR expression on 2G (A, B) and 3G (C, D) T cells was evaluated
by flow cytometry before and after co-culture. T cells were gated as viable singlet cells expressing CD3.
Statistical differences were calculated usingWilcoxon matched pairs signed rank test (start vs B/IL-2 3G;
p = 0.0313, 2G; p = 0.0313). Healthy donors are shown as grey circles and CLL patients as black squares.
doi:10.1371/journal.pone.0144787.g001
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Intracellular signaling downstream CAR T cells
To evaluate the activation status of intracellular signaling pathways downstream CAR and sig-
naling pathways activated secondary to CAR stimulation, CAR T cells were stimulated with
autologous B cells and analyzed by the PamGene tyrosine kinase array. The Tyrosine Kinase
PamChip1 Array by PamGene consists of 144 peptides with known phosphorylation sites
derived from 100 different proteins. Intact cells or cell lysates can be stimulated and analyzed
for the presence of active kinases that will phosphorylate the Array peptides. Hence, an
increased phosphorylation of a certain peptide do not mean that the cells contained that certain
peptide, but has activated the kinases that can act on those peptides. CAR T cells showed an
overall increased activation status compared to Mock transduced cells and 3G T cells were gen-
erally more activated than 2G T cells. The activation status in 3G CARs was also maintained
over time compared to 2G CARs. Nevertheless, the pattern of what kinases that were activated
was similar between 2G and 3G. As expected, signaling molecules downstream of the TCR
were phosphorylated also by stimulating CAR receptors such as CD3 zeta, LAT, LCK and
ZAP-70. Interestingly, also other proteins involved in regulation of the cell cycle (CDK2), cell
adhesion (Paxillin, PECAM-1) and exocytosis (Annexins) were phosphorylated. Stimulating
cell adhesion may be of importance especially for treatment of solid tumors, and increased exo-
cytosis may result in enhanced serial killing capacity. The most interesting phosphorylation
targets are listed in Fig 3 while the complete array is shown in S1 Table
Fig 2. Themajority of CAR T cells are CD8+ effector or effector memory cells. Lineage (A; CD3+ CD8+),
exhaustion phenotype (B; PD-1+ Tim-3+) and memory/effector status (C) were evaluated by flow cytometry
at start and after co-culture with autologous B cells and IL-2 or IL-2 alone. Graphs are showing CAR+ T cells,
gated as viable singlet cells expressing CD3 and CAR. For memory/effector status the cells were divided into
the following subtypes: naïve: CD45RA+ CCR7+, effector: CD45RA+ CCR7-, central memory (CM):
CD45RA- CCR7+ and effector memory (EM): CD45RA- CCR7-. There was no statistical difference in
expression of lineage or exhaustion markers between the different time-points or between groups. T cells of
effector memory phenotype increased (IL-2 vs B/IL-2 3G: p = 0.0836, 2G: p = 0.1232), while effector cells
decreased (start vs B/IL-2 3G: p = 0.0625, 2G: p = 0.0625). There was also a tendency to increased number
of central memory cells (start vs B/IL-2 3G: p = 0.0625, 2G: p = 0.0625). Error bars represent SEM. Statistical
differences were calculated with unpaired t-test with Welch correction andWilcoxon matched-pairs signed
rank test.
doi:10.1371/journal.pone.0144787.g002
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Since the PamGene array only demonstrate the capacity of cells to phosphorylate a library
of peptides, we confirmed some of the data using the MILLIPLEX1MAP T-Cell Receptor Sig-
naling Magnetic Bead Kit 7-Plex andWestern blots. LAT, ZAP-70, SYK and Erk all showed a
similar pattern of higher levels of phosphorylated proteins in 3G CAR T cells compared to 2G
T cells (Fig 4). Hence, 3G CAR T cells show a different, more activated pattern of intracellular
signaling compared to 2G CAR T cells.
2G and 3G CARs exhibit equal in vitro cytotoxicity
Cytotoxic capacity was evaluated with a chromium release assay before and after one month’s
expansion. 3G CARs were equally efficient as 2G CAR T cells in specific killing of CD19+ target
cells (Fig 5A). The cells also showed some activity against the NK target cell line K562 (data
not shown) but this killing was not related to CAR expression as Mock or untransduced T cells
showed similar background activity. After co-culture with B cells +/- IL-2, T cells cultured with
B cells and IL-2 maintained their cytotoxic capacity (Fig 5C) while T cells cultured with IL-2
alone (Fig 5B) showed decreased cytotoxicity compared to the levels showed prior to co-cul-
ture. This effect was most clearly seen with CAR T cells derived from CLL patients.
Antigen-driven CAR T cell expansion
Proliferation was analyzed weekly during expansion, prior to the addition of autologous B cells
and IL-2. After one week’s stimulation, 3G CAR T cells proliferated better than Mock
Fig 3. Tyrosine kinase phosphorylation downstream CAR. Tyrosine kinase phosphorylation in mock, 2G
or 3G transduced T cells, 1 and 3 hours post stimulation with autologous B cells. Darker color indicates
increased signal intensity. Data was normalized for CAR expression. A selection of the most interesting
phosphorylation targets in the assay is shown. Complete array data can be found in S1 Table.
doi:10.1371/journal.pone.0144787.g003
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transduced cells (p = 0.0302) (Fig 6A). The proliferation capacity was increased by adding B
cells to the IL-2 stimulation (Fig 6B). Both 3G and 2G CAR T cells proliferated more exten-
sively than Mock cells (p = 0.0003 and p = 0.0419, respectively). 3G cells proliferated better
than 2G upon antigen stimulation (based on exclusion of the outlier seen in the B/IL-2 2G
group, p = 0.0075). CAR T cells efficiently recognized and killed the autologous B cells that
were added to the T cell expansions, while they remained in cultures with Mock T cells
(Fig 6C).
Fig 4. Adaptor proteins involved in TCR signaling are phosphorylated downstream CAR. Phosphorylation of CD3ε (A), LAT (B), ZAP-70 (C), LCK (D),
SYK (E), Erk (F) and CREB (G) at start and after stimulation with B cells and IL-2 is demonstrated using MILLIPLEX1MAP T-Cell Receptor Signaling kit.
The mean value is indicated in the Figure and the dotted line indicates background levels. Data was normalized for CAR expression. Statistical differences
were calculated by unpaired t-test with Welch correction andWilcoxon matched-pairs signed rank test (* = p<0.05).
doi:10.1371/journal.pone.0144787.g004
Fig 5. The presence of antigen stimulates andmaintains the cytotoxic capacity of CAR T cells. The Figure demonstrates cytotoxicity of CAR T cells
generated from CLL patients (n = 3) against CD19+ Daudi before (A) and after co-culture with IL-2 (B) and autologous B cells (C). The cytotoxicity was
normalized to CAR expression due to variation of expression. Current CAR expression at each specific time-point was used for normalization. Error bars
represent SEM.
doi:10.1371/journal.pone.0144787.g005
Increased Signaling Activity in Third Generation CAR T Cells
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CAR T cells respond to antigen with release of IFNγ and Granzyme B
Cell supernatants were collected 24 hours post stimulation and analyzed for IFNγ and Gran-
zyme B using ELISA. IFNγ was mainly seen in supernatants from the T cell expansion cultures
where the CAR T cells had been stimulated with antigen, while Mock and untransduced cells
showed low or undetectable levels (Fig 7A). Granzyme B could be detected in all groups, yet
the highest levels were detected in supernatants from CAR T cells cultured with B cells and IL-
2 (Fig 7B). IFNγ and Granzyme B levels were higher at first stimulation compared to the levels
after repeated stimulations, with the highest levels secreted from CAR T cells stimulated with
IL-2 and autologous B cells.
In vivo tumor cell elimination and expansion of 2G and 3G T cells
Mice (Nu/Nu) were injected subcutaneously with Daudi cells and mice with established tumors
were treated with one 3G or 2G CAR T cell infusion. Both 3G and 2G CAR T cells efficiently
reduced tumor growth (Fig 8A). Additionally, humanized NSG mice, engrafted with UBC-
derived CD34+ cells (Fig 8B) were used to assess the expansion of autologous T cells transduced
Fig 6. 3G CAR T cells show increased proliferation compared to 2G CAR. Proliferation was determined each week through cell count prior to addition of
B cells. The Figure shows T cell expansion from start to stimulation with IL-2 (A) or B cells and IL-2 (B). Data was normalized for CAR expression. (C)
Remaining viable B cells in co-culture at endpoint (after 2–4 B cell stimulations, 4:1 ratio) analyzed by flow cytometry. The mean is indicated in the Figure.
Statistical differences were calculated by unpaired t-test with Welch correction (* = p<0.05, ** = p<0.01, *** = p<0.001).
doi:10.1371/journal.pone.0144787.g006
Fig 7. CAR T cells release IFNγ and Granzyme B in response to antigen. Culture supernatants were collected 24h after stimulation at day 1 (start) and at
endpoint (end). CAR T cells responded to antigen stimulation through secretion of IFNγ (A, B) and Granzyme B (C, D). IFNγ levels were higher in in the
groups stimulated with both B cells and IL-2 compared to B cells alone, both at the beginning (3G: p = 0.0418, 2G: p = 0.1389) and at the end of co-culture
(3G: p = 0.0228 p = 2G: p = 0.1446). Data was normalized for CAR expression. Error bars represent SEM. Statistical differences were calculated by unpaired
t-test with Welch correction.
doi:10.1371/journal.pone.0144787.g007
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with 3G or 2G T cells. 2G and 3G CAR T cells expanded equally in vivo. Although 3G CAR T
cells showed a more rapid initial expansion after infusion no statistically significant differences
could be found in the expansion patterns of 2G and 3G T cells (Fig 8C). In addition, both 2G
and 3G T cells successfully eliminated circulating CD19+ B cells displaying comparable in vivo
efficacy (Fig 8D). Mice euthanized by day 60 (S3B Fig) or day 100 (S3C Fig) also showed com-
parable T cell persistence as confirmed by immunophenotype in spleen and bone marrow. No
CD19+ B cells were detected in mice receiving either 2G or 3G T cells.
Discussion
The recent success stories of immunotherapy have demonstrated the potency of the immune
system to specifically target and kill tumor cells. The induction of Th1 immunity with T cells,
M1 macrophages and NK cells as effectors has proven important for potent and sustained
responses. Ex vivo engineering of the patients’ own T cells with CAR receptors to generate an
army of trained killers is now under evaluation for both leukemia, lymphoma as well as for
other malignancies [35]. There are multiple options for CAR design and the optimal CAR is
yet to be determined. Likely, there are more than one design that will allow for proper T cell
Fig 8. CAR T cells eliminate tumor cells and expand in vivo.Mice (Nu/Nu) were injected s.c. with Daudi cells and treated with vehicle, mock, 2G or 3G
CAR T cells (6 mice per group). Tumor growth is shown in A. 2G and 3G CAR T cells were infused in NSGmice engrafted with human CD34+ cells (10 mice
per group). Successful engraftment is shown as detectable CD45 and CD19 cells in two representative mice (B). Migration and persistence in vivo was
monitored by GFP-FireFly(FF)-luciferase. The bioluminescence signal frommice infused with 2G (red line) or 3G (black line) T cells is shown in C. At day 30,
peripheral blood was collected and the presence of CAR+ T cells and B cells (CD19+) were detected with flow cytometry. T cells and B cells were gated from
the CD45+ population. A representative sample is shown in D.
doi:10.1371/journal.pone.0144787.g008
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activation and persistence. For T cell activation to occur two important signals are required;
antigen recognition via binding of peptide-MHC complexes to the T cell receptor (TCR) and
costimulation via binding of e.g. CD80/CD86 to CD28 on the T cell. Activation gives rise to
upregulation of anti-apoptotic proteins and secretion of cytokines such as IL-2 providing the
cells with stimulatory survival signaling [36]. 4-1BB is induced by TCR-signaling. If cross-
linked, 4-1BB give rise to increased proliferation and cytokine secretion in the activated T cell
[37]. 2G and 3G CARs utilize the costimulatory potential of molecules such as CD28 and 4-
1BB to provide the CAR T cells with increased survival signaling. Zhong et al showed higher
protein levels of Bcl-xL in antigen-stimulated αPSMA-CAR T cells transduced with a CAR
containing both CD28 and 4-1BB. These cells also showed the lowest levels of apoptosis, com-
pared to CAR constructs with only CD28 or 4-1BB or no costimulatory molecules, indicating
that the addition of 4-1BB convey an increased resistance to apoptosis [38]. However, there are
several other molecules of interest to include alone or in different combinations in CARs, such
as OX40 [14, 39, 40] and CD27 [41].
In this study we aimed to evaluate the functional capacity of CD19-targeting 3G CAR T
cells with CD28, 4-1BB and CD3 zeta signaling domains and compare their capacity to 2G
CARs lacking 4-1BB as well as to Mock transduced T cells. CAR T cells could be generated
from both healthy donors and CLL patients but the CAR expression of 2G CARs was always
slightly higher than 3G CAR expression both related to number of positive cells and number of
CAR molecules per cell as judged by a higher mean fluorescent intensity upon analysis of CAR
expression. Hence, for some of the functional assays we correlated the data to the number of
CAR+ cells to be able to more appropriately compare the ability of the 2G and 3G cells. Fur-
ther, the T cells were analyzed before and after repeated stimulation with autologous B cells to
determine the persistence of CAR T cells.
Co-culture of CAR T cells with autologous B cells stimulated an accumulation of both 3G
and 2G CAR positive cells in the cultures, which was not seen in cultures with IL-2 alone. Fur-
ther, antigen-driven proliferation generated a memory-like phenotype of the cultured CAR T
cells with low expression of the exhaustion markers PD-1 and Tim-3. There is emerging evi-
dence that such a phenotype will generate a better in vivo response. For example, in a primate
model genetically modified T cells derived of central memory phenotype was shown to persist
longer than effector cells derived from effector memory cells [42]. Further, Kalos et al reported
that the persisting cells in their CLL patients treated with 2G 4-1BB CAR T cells were of central
memory phenotype [2]. A major concern of using more differentiated cells is the risk of trans-
ferring exhausted cells. In our CAR T cells cultures, CAR+ cells with a naïve phenotype are also
persisting independently of repeated antigen stimulation. It has been suggested that CAR T
cells with a more naïve phenotype may be preferred to effector T cells to increase survival and
generation of memory subtypes. In a murine model, Hinrich et al showed that effector cells
derived from naïve cells displayed superior antitumor activity upon adoptive transfer com-
pared to central memory T cells [43]. Further, Gattinoni et al reported that stem-like T mem-
ory cells (CD8+, CD45RA+, CCR7+, CD62L+, CD27+, CD28+) phenotypically resembled
naïve cells but carried traits of memory cells [44]. Xu et al noted that the frequency of CD8+,
CD45RA+, CCR7+ cells within the infused product correlated with the in vivo expansion of
CD19-targeting CAR T cells in lymphoma patients [45]. In our study, the antigen-expanded T
cells were mainly of memory phenotype while maintaining a small population of phenotypi-
cally naïve cells and low levels of exhaustion markers. Hence, antigen-driven expansion of
CAR T cells may be an interesting approach for GMP production prior to clinical use. How-
ever, 3G and 2G CAR T cells did not differ in regard to phenotype upon repeated antigen stim-
ulation. The cytotoxic capacity of 2G and 3G αCD19-CAR T cells was also similar pre and post
prolonged culture with IL-2 or with the addition of autologous B cells. However, the cytotoxic
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capacity of both 2G and 3G CARs was lower after expansion with only IL-2 suggesting that anti-
gen-driven expansion maintains potent T cells rather than induces exhaustion. Artificial APCs
can also efficiently expand CAR+ T cells [46] and can become an important tool when tumor
material is scarce and for tumors where expression of co-stimulatory molecules is low or lacking.
The proliferative capacity of 3G CAR T cells upon IL-2 stimulation was higher than that of
2G CAR T cells. 2G CARs were not significantly different fromMock or untransduced cells.
Upon repeated stimulation with autologous B cells, both 2G and 3G CAR T cells showed
increased proliferation capacity compared to Mock and untransduced cells. With the exception
of one donor, 3G CARs had still a higher proliferative capacity than 2G CARs. Barrett et al
emphasizes the importance of maintaining proliferation capacity during the ex vivo expansion
phase of manufacturing, suggesting in the light of recent studies that proliferation capacity
might be more important than cytotoxic capacity [47]. Yet, distinct differences in cytotoxicity
and persistence between the different types of CAR T cells will most likely be revealed in vivo
since the complex network of stimulatory and inhibitory pathways are difficult to mimic in
preclinical settings. Tammana et al showed that CARs with costimulatory molecule 4-1BB
alone or combined with CD28 provided a more robust antitumor response in vivo compared to
CARs with CD28 alone or without costimulatory molecules [18]. Zhong et al demonstrated an
increased survival of mice treated with a 3G CAR (CD28, 4-1BB) compared to either 2G
(CD28 or 4-1BB) or 1G CAR T cells [38]. 2G and 3G CAR T cells efficiently reduced tumor
volume in a subcutaneous tumor model and eliminated human CD19+ cells in NSG mice. Pre-
vious data has suggested elimination of CAR T cells containing a long CH2-CH3 spacer in
NSG mice [48], yet CAR T cells in our studies could still be detected at day 100 in NSG mice,
also the percentage of CAR+ cells detected was larger for 3G than 2G.
The intracellular signaling events downstream different CARs affect the efficiency and lon-
gevity of the T cells. Considering the use of the CD3 zeta domain in the CAR, TCR-associated
proteins will likely participate in CAR signaling but it is not known to what extent other signal-
ing pathways are affected in different types of CAR T cells. In this study, the PamGene station
was utilized to investigate phosphorylation status of multiple targets. Upon antigen stimulation
both 3G and 2G T cells could rapidly activate kinases that have the capacity to phosphorylate a
number of proteins. 3G T cells showed a higher activation status than 2G but both were
increased compared to Mock T cells. After 3 hours the activation status declined but more
slowly in 3G T cells. As expected, all the common proteins downstream the TCR signaling
pathway were activated such as CD3 zeta, LAT, LCK and ZAP-70. These data were confirmed
also by analyzing the T cells using the MILLIPLEX1MAP T-Cell Receptor Signaling kit. 3G
CAR T cells had a significantly higher phosphorylation status on antigen-mediated signaling
molecules compared to 2G CAR T cells. The PamGene array also revealed other possibly phos-
phorylated molecules that will need further confirmation. For example, Calmodulin phosphor-
ylation was increased post antigen stimulation. Calmodulin is a calcium-binding messenger
protein important for many Ca2+ regulated pathways in lymphocytes and other cells. For
example, upon Ca2+ release from the endoplasmatic reticulum (ER), calcium-bound Calmod-
ulin activates the phosphatase calcineurin, which in turn promotes NFAT-mediated IL-2 tran-
scription [49]. Further, both Annexin A1 and A2 phosphorylation was increased in 2G and 3G
CAR T cells. Annexins are a family of Ca2+ dependent phospholipid-binding proteins impor-
tant in various cellular processes, such as those regulating changes in cell shape and organiza-
tion of vesicles and exocytosis [50]. They are also involved in inflammation and apoptosis [51].
Annexin A1 promotes T cell activation and seems important to fine-tune TCR signaling. How-
ever, it has an inhibitory effect on innate immune cells such as neutrophils [52] and inhibits
LPS-mediated DC activation [53], Annexin A2 is phosphorylated upon T cell activation and
may be involved in signal transduction during cellular proliferation and differentiation [54].
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CDK2 is a protein involved in the progression of the cell cycle as CDK binding to cyclin E
during G1 phase promotes the transition from G1 to S phase. Antigen stimulation together
with costimulation activates a CDK cascade including CDK2. However, in the absence of costi-
mulation the T cells are entering a state of anergy, which is enforced by the CDK inhibitory
protein p27kip1. The major target of p27kip1 is CDK2. In a study of allograft rejection it was
shown that CDK2 was highly active in T cells that infiltrated the allograft [55]. Interestingly,
cyclin E and CDK2 can in a collaborative effort phosphorylate FoxP3, which reduces FoxP3
stability [56] and may explain the transient FoxP3 expression in recently activated T cells. Cor-
respondingly, it was recently shown that CDK2 inhibition promotes induction of T regulatory
cells by enhancing the TGFβ-mediated Smad3 signaling pathway [57]. Hence, the strong and
sustained phosphorylation of CDK2 in 3G T cells may be an important factor contributing to
the enhanced proliferation compared to 2G T cells.
There were also enhanced phosphorylation of molecules that can potentially be involved in
self-regulation of the antigen-induced activation such as Crk, Protein 4.1R, FAK and DYRK1A.
Crk adaptor molecules interact with a number of signaling molecules in the cell. Their function
is not fully understood but there is one report stating that T cells lacking both Crk and CrkL
have a defective chemotactic response to multiple chemokines and may show defective diape-
desis. In a cutaneous DTH model, Crk and CrkL were required for efficient T cell migration to
sites of inflammation. Crk proteins also controlled T cell activation [58]. Nevertheless, another
report demonstrates that Crk is cleaved in response to ER stress to exert a pro-apoptotic func-
tion. Crk -/- cells were strongly resistant to ER stress-induced apoptosis [59]. Our data show
that Crk activation was somewhat higher in 2G CAR T cells than in 3G CARs. Protein 4.1R
binds to LAT and inhibits its phosphorylation of ZAP70 thereby negatively regulating TCR-
mediated signaling [60]. FAK instead inhibits TCR signaling by phosphorylation of Lck [61]. If
present in T cells, DYRK1A may regulate T cell activation by inhibition of NFAT activation
since it has been shown that DYRK1A is involved in NFAT activation in other cells such as car-
diomyocytes [62] and in the Drosophila model [63].
Despite of CAR T cell expansion, there was a remaining CAR+ naïve T cell population in
the cultures. Ras is activated by TCR stimulation and has a role in activating the MAP kinases
leading towards cell growth. Ras is inactivated by Ras GTPase-activating proteins (RasGAPs)
such as RASA1. In a paper by Lapinski PE et al it was shown that RASA1 is an important regu-
lator of thymocyte survival during positive selection as well as promoting the survival of naïve
T cells in the periphery [64]. In RAFA1 deficient mice, the total number of naïve CD4 and
CD8 T cells was reduced by 50–90% and it was shown that RASA1 deficient mice had an
impaired IL-7-mediated survival of naïve T cells. There was phosphorylation of RASA1 pep-
tides in the PamGene array indicating that there may be an active process ongoing to maintain
a phenotype of naïve cells during antigen-driven expansion. However, this assumption needs
to be experimentally verified.
Other proteins that can be phosphorylated in CAR T cells post activation are Paxillin,
PECAM-1 and EGFR. Paxillin is a cytoskeletal adaptor protein that localizes to the microtu-
bule-organizing center in T cells and is part of the immunological synapse of cytotoxic T cells
[65]. Paxillin is phosphorylated downstream of ERK, hence, connecting it to the TCR-mediated
signaling. Another molecule involved in cell adhesion is PECAM-1. Little is known about
PECAM-1 in T cells but in a recent paper Proust R et al describes that PECAM-1 may be
involved in cell adhesion in T cells [66]. Both Paxillin and PECAM-1 was highly phosphory-
lated by 3G CAR T cells and the phosphorylation was sustained also 3 hours post antigen stim-
ulation. Finally, phosphorylation of EGFR was seen post antigen stimulation in the CAR T
cells. EGFR is ubiquitously expressed but has been regarded absent from hematopoietic cells.
However, EGFRs have been demonstrated in some immune cell populations and it has been
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shown that T regulatory cells express EGFR during inflammatory conditions. In PBMCs, CD4
T cells had low expression levels while it was absent on CD8 T cells [67]. However, it is not
known if the EGFR is present on activated T cells. Nevertheless, the EGFR and the TCR share a
common signaling pathway via the ERK-MAP kinase molecule and EGFR signaling in T cells
could possibly enhance their survival and activation status. Our data suggests that the EGFRs
can be efficiently phosphorylated by activated T cells if they are indeed present and 3G T cells
can sustain the activation also 3 hours post antigen stimulation.
Taken together, these data demonstrates that antigen-driven expansion of CAR T cells gen-
erates memory-like T cells with maintained cytotoxic capacity. Further, while the phenotype
and cytotoxic capacity post repeated antigen stimulation were similar between 3G and its pre-
decessor (2G). The 2G and 3G CAR T cells also showed efficient killing in vivo. 3G CAR T cells
had an increased activation of intracellular signaling pathways concerning both TCR signaling
and adhesion molecules compared to 2G CARs. However, the tyrosine kinase array indicates
potentially interesting pathways that can be activated or blocked to generate even more effi-
cient CAR designs.
Supporting Information
S1 Fig. Experimental outline of co-culture experiments and overview of cell preparation. A.
Experimental outline of the co-culture experiment. 3G, 2G CAR T, mock or untransduced T
cells were cultured with autologous B cells, IL-2 or the combination of the two. Proliferation
was assessed every week. CAR T cell phenotype and cytotoxic capacity was analyzed before
and after co-culture using flow cytometry and chromium release assay, respectively. B. Over-
view of cell preparation. Autologous T and B cells were isolated from healthy donors and CLL
patients using MACS beads. The purity of the B cell population (αCD20-isolation) was con-
firmed with αCD19 FACS staining (mean expression was 96.4% ranging from 90.5 to 99.5). T
cells were isolated from the CD20- fraction using pan T beads, rendering an unlabeled CD3+
population with a mean CD3 expression of 99.3% (range 99–99.7).
(TIF)
S2 Fig. Expression levels of memory markers in the CAR negative populations. CAR- T
cells were gated as viable singlet CD3+ CAR- cells. Memory phenotype defined as; naïve:
CD45RA+, CCR7+, effector: CD45RA+, CCR7-, central memory (CM): CD45RA-, CCR7+,
effector memory (EM): CD45RA-, CCR7. CAR negative T cells show similar expression pat-
tern of memory markers as CAR positive cells before co-culture. However, after co-culture
with antigen, the increase in memory phenotype and decrease in effector cells was only seen in
the CAR positive population.
(TIF)
S3 Fig. Persistence of CAR T cells in vivo. Comparable expression levels of FF-luciferase was
seen in 2G and 3G CAR+ T cells as measured by GFP expression (A). NSGMice were eutha-
nized on day 60 (B) or day 100 (C). CD19+ B cells were completely eliminated and longterm
persistence of CAR+ T cells was seen. T and B cells are gated from the CD45+ population. Pan-
els show phenotype from a representative mouse for each construct.
(TIF)
S1 Table. Activation of tyrosine kinases in CAR T cells. The table demonstrates mean values
from the tyrosine kinase array by PamGene. CAR T cells (2G and 3G) as well as Mock T cells
were stimulated with autologous B cells for 1 and 3 hours. The cells were purified using MACS
beads and lysed prior to analysis. Data was normalized for CAR expression.
(DOCX)
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